Glioblastoma multiforme-derived extracellular vesicles drive normal astrocytes towards a tumour-enhancing phenotype

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 373, Issue 1737, 2018, Pages

  Oushy, Soliman ^a,b   Hellwinkel, Justin E ^a,b   Wang, Mary ^b   Nguyen, Ger J ^b   Gunaydin, Dicle ^b   Harland, Tessa A ^a,b   Anchordoquy, Thomas J ^c   Graner, Michael W ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Department of Neurosurgery ^*  (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Astrocytes; Exosomes; Extracellular vesicles; Glioblastoma multiforme; Microenvironment; Signalling

Indexed keywords

ANATOMY; BIOLOGY; BIOTRANSFORMATION; CATION; CELLS AND CELL COMPONENTS; COLONY; GROWTH; PHENOTYPE; PROTEIN; SIGNALING; TUMOR;

CYTOKINE;

ASTROCYTE; CELL MOTION; CELL PROLIFERATION; EXOSOME; GLIOBLASTOMA; HUMAN; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

ASTROCYTES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYTOKINES; EXTRACELLULAR VESICLES; GLIOBLASTOMA; HUMANS; PHENOTYPE; TUMOR MICROENVIRONMENT;

EID: 85036532163     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2016.0477     Document Type: Article

References (87)

1. Stupp R et al. 2009 Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459-466. (doi:10.1016/S1470-2045(09)70025-7)
2. Sizoo EM, Dirven L, Reijneveld JC, Postma TJ, Heimans JJ, Deliens LJ. 2014 Measuring health-related quality of life in high-grade glioma patients at the end of life using a proxy-reported retrospective questionnaire [Internet]. http://www.ncbi.nlm.nih.gov/pubmed/24162875 283-290.
3. Lee EQ, Nayak L, Wen PY, Reardon DA. 2013 Treatment options in newly diagnosed glioblastoma. Curr. Treat. Options Neurol. 15, 281-288. (doi:10.1007/s11940-013-0226-9)
4. Cohen MH, Shen YL, Keegan P, Pazdur R. 2009 FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 14, 1131-1138. (doi:10.1634/theoncologist.2009-0121)
5. Norden AD, Drappatz J, Wen PY. 2008 Novel anti-angiogenic therapies for malignant gliomas. LancetNeurol.7,1152-1160. (doi:10.1016/S1474-4422(08)70260-6)
6. Dixit S. 2014 Immunotherapy for high-grade glioma. Future Oncol. 10, 911-915. (doi:10.2217/ fon.14.20)
7. Raposo G, Stoorvogel W. 2013 Extracellular vesicles: exosomes, microvesicles, and friends. J. Cell Biol. 200, 373-383. (doi:10.1083/jcb.201211138)
8. Yanez-Mo M et al. 2015 Biological properties of extracellular vesicles and their physiological functions. J. Extracell. Vesicles 4, 27066. (doi:10.3402/jev.v4.27066)
9. D’Asti E, Chennakrishnaiah S, Lee TH, Rak J. 2016 Extracellular vesicles in brain tumor progression. Cell. Mol. Neurobiol. 36, 383-407. (doi:10.1007/s10571-015-0296-1)
10. Redzic JS, Ung TH, Graner MW. 2014 Glioblastoma extracellular vesicles: reservoirs of potential biomarkers. Pharmacogenomics Pers. Med. 7, 65-77. (doi:10.2147/PGPM.S39768)
11. Parolini I et al. 2009 Microenvironmental pH is a key factor for exosome traffic in tumor cells. J. Biol. Chem. 284, 34211-34222. (doi:10.1074/jbc.M109.041152)
12. Webber J, Steadman R, Mason MD, Tabi Z, Clayton A. 2010 Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res. 70, 9621-9630. (doi:10.1158/0008-5472.CAN-10-1722)
13. Skog J et al. 2008 Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 10, 1470-1476. (doi:10.1038/ ncb1800)
14. Suetsugu A, Honma K, Saji S, Moriwaki H, Ochiya T, Hoffman RM. 2013 Imaging exosome transfer from breast cancer cells to stroma at metastatic sites in orthotopic nude-mouse models. Adv. Drug Deliv. Rev. 65, 383-390. (doi:10.1016/j.addr. 2012.08.007)
15. Thery C, Ostrowski M, Segura E. 2009 Membrane vesicles as conveyors of immune responses. Nat. Rev. Immunol. 9, 581-593. (doi:10.1038/nri2567)
16. Hellwinkel JE, Redzic JS, Harland TA, Gunaydin D, Anchordoquy TJ, Graner MW. 2016 Glioma-derived extracellular vesicles selectively suppress immune responses. Neuro Oncol. 18, 497-506. (doi:10. 1093/neuonc/nov170)
17. Dolo V, Ginestra A, Cassara D, Ghersi G, Nagase H, Vittorelli ML. 1999 Shed membrane vesicles and selective localization of gelatinases and MMP-9/ TIMP-1 complexes. Ann. N Y Acad. Sci. 878, 497-499. (doi:10.1111/j.1749-6632.1999.tb07707.x)
18. Lv MM et al. 2014 Exosomes mediate drug resistance transfer in MCF-7 breast cancer cells and a probable mechanism is delivery of P-glycoprotein. Tumour Biol. 35, 10773-10779. (doi:10.1007/ s13277-014-2377-z)
19. Hakulinen J, Sankkila L, Sugiyama N, Lehti K, Keski-Oja J. 2008 Secretion of active membrane type 1 matrix metalloproteinase (MMP-14) into extracellular space in microvesicular exosomes. J. Cell Biochem. 105, 1211-1218. (doi:10.1002/ jcb.21923)
20. Lugini L, Valtieri M, Federici C, Cecchetti S, Meschini S, Condello M, Signore M, Fais S. 2016 Exosomes from human colorectal cancer induce a tumor-like behavior in colonic mesenchymal stromal cells. Oncotarget 7, 50086-50098. (doi:10.18632/oncotarget.10574)
21. Corrado C, Saieva L, Raimondo S, Santoro A, De Leo G, Alessandro R. 2016 Chronic myelogenous leukaemia exosomes modulate bone marrow microenvironment through activation of epidermal growth factor receptor. J. Cell Mol. Med. 20, 1829-1839. (doi:10.1111/jcmm.12873)
22. Maida Y, Takakura M, Nishiuchi T, Yoshimoto T, Kyo S. 2016 Exosomal transfer of functional small RNAs mediates cancer-stroma communication in human endometrium. Cancer Med. 5, 304-314. (doi:10. 1002/cam4.545)
23. Paggetti J et al. 2015 Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts. Blood 126, 1106-1117. (doi:10.1182/blood-2014-12-618025)
24. Melo SA et al. 2014 Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell 26, 707-721. (doi:10.1016/j.ccell.2014.09.005)
25. Epple LM, Griffiths SG, Dechkovskaia AM, Dusto NL, White J, Ouellette RJ, Anchordoquy TJ, Bemis LT, Graner MW. 2012 Medulloblastoma exosome proteomics yield functional roles for extracellular vesicles. PLoS ONE 7, e42064. (doi:10.1371/journal. pone.0042064)
26. Chen WW et al. 2013 BEAMing and droplet digital PCR analysis of mutant IDH1 mRNA in glioma patient serum and cerebrospinal fluid extracellular vesicles. Mol. Ther. Nucleic Acids 2, e109. (doi:10. 1038/mtna.2013.28)
27. Akers JC et al. 2013 MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development. PLoS ONE 8, e78115. (doi:10.1371/journal.pone. 0078115)
28. Liang CC, Park AY, Guan JL. 2007 In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat. Protoc. 2, 329-333. (doi:10.1038/nprot.2007.30)
29. Van Deun J, Mestdagh P, Sormunen R, Cocquyt V, Vermaelen K, Vandesompele J, Bracke M, De Wever O, Hendrix A. 2014 The impact of disparate isolation methods for extracellular vesicles on downstream RNA profiling. J. Extracell. Vesicles 3, 24858. (doi:10. 3402/jev.v3.24858)
30. Hong BS et al. 2009 Colorectal cancer cell-derived microvesicles are enriched in cell cycle-related mRNAs that promote proliferation of endothelial cells. BMC Genomics 10, 556. (doi:10.1186/1471-2164-10-556)
31. Demory Beckler M et al. 2013 Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS. Mol. Cell Proteomics 12, 343-355. (doi:10.1074/mcp. M112.022806)
32. Skogberg G et al. 2013 Characterization of human thymic exosomes. PLoS ONE 8, e67554. (doi:10. 1371/journal.pone.0067554)
33. Cordell PA, Kile BT, Standeven KF, Josefsson EC, Pease RJ, Grant PJ. 2010 Association of coagulation factor XIII-A with Golgi proteins within monocyte-macrophages: implications for subcellular trafficking and secretion. Blood 115, 2674-2681. (doi:10. 1182/blood-2009-08-231316)
34. Crane CA, Ahn BJ, Han SJ, Parsa AT. 2012 Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy. Neuro Oncol. 14, 584-595. (doi:10.1093/neuonc/ nos014)
35. Gielen PR, Schulte BM, Kers-Rebel ED, Verrijp K, Petersen-Baltussen HM, ter Laan M, Wesseling P, Adema GJ. 2015 Increase in both CD14-positive and CD15-positive myeloid-derived suppressor cell subpopulations in the blood of patients with glioma but predominance of CD15-positive myeloid-derived suppressor cells in glioma tissue. J. Neuropathol. Exp. Neurol. 74, 390-400. (doi:10.1097/NEN.0000000000000183)
36. Antonios JP et al. 2017 Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. Neuro Oncol. 19, 796-807. (doi:10. 1093/neuonc/now287)
37. Dwyer J, Hebda JK, Le Guelte A, Galan-Moya EM, Smith SS, Azzi S, Bidere N, Gavard J. 2012 Glioblastoma cell-secreted interleukin-8 induces brain endothelial cell permeability via CXCR2. PLoS ONE 7, e45562. (doi:10.1371/journal.pone.0045562)
38. Gilbertson RJ, Rich JN. 2007 Making a tumour’s bed: glioblastoma stem cells and the vascular niche. Nat. Rev. Cancer 7, 733-736. (doi:10.1038/nrc2246)
39. Giusti I, Delle Monache S, Di Francesco M, Sanita P, D’Ascenzo S, Gravina GL, Festuccia C, Dolo V. 2016 From glioblastoma to endothelial cells through extracellular vesicles: messages for angiogenesis. Tumour Biol. 37, 12743-12753. (doi:10.1007/ s13277-016-5165-0)
40. Kucharzewska P et al. 2013 Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc. Natl Acad. Sci. USA 110, 7312-7317. (doi:10.1073/pnas.1220998110)
41. van der Vos KE et al. 2016 Directly visualized glioblastoma-derived extracellular vesicles transfer RNA to microglia/macrophages in the brain. Neuro Oncol. 18, 58-69. (doi:10.1093/ neuonc/nov244)
42. Yeung YT, McDonald KL, Grewal T, Munoz L. 2013 Interleukins in glioblastoma pathophysiology: implications for therapy. Br. J. Pharmacol. 168, 591-606. (doi:10.1111/bph.12008)
43. Albulescu R, Codrici E, Popescu ID, Mihai S, Necula LG, Petrescu D, Teodoru M, Tanase CP. 2013 Cytokine patterns in brain tumour progression. Mediators Inflamm. 2013, 979748. (doi:10.1155/2013/979748)
44. Joseph JV et al. 2015 Serum-induced differentiation of glioblastoma neurospheres leads to enhanced migration/invasion capacity that is associated with increased MMP9. PLoS ONE 10, e0145393. (doi:10.1371/journal.pone.0145393)
45. Wang F et al. 2015 Activation of toll-like receptor 2 promotes invasion by upregulating MMPs in glioma stem cells. Am. J. Transl. Res. 7, 607-615.
46. Veeravalli KK, Rao JS. 2012 MMP-9 and uPAR regulated glioma cell migration. Cell Adh. Migr. 6, 509-512. (doi:10.4161/cam.21673)
47. Harshyne LA, Nasca BJ, Kenyon LC, Andrews DW, Hooper DC. 2016 Serum exosomes and cytokines promote a T-helper cell type 2 environment in the peripheral blood of glioblastoma patients. Neuro Oncol. 18, 206-215. (doi:10.1093/neuonc/nov107)
48. Sonabend AM, Rolle CE, Lesniak MS. 2008 The role of regulatory T cells in malignant glioma. Anticancer Res. 28, 1143-1150.
49. Jackson C, Ruzevick J, Phallen J, Belcaid Z, Lim M. 2011 Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment. Clin. Dev. Immunol. 2011, 732413. (doi:10.1155/2011/732413)
50. Lefranc F, Rynkowski M, DeWitte O, Kiss R. 2009 Present and potential future adjuvant issues in high-grade astrocytic glioma treatment. Adv. Tech. Stand. Neurosurg. 34, 3-35. (doi:10.1007/978-3-211-78741-0_1)
51. Lv S, Dai C, Liu Y, Sun B, Shi R, Han M, Bian R, Wang R. 2015 Cell surface protein C23 affects EGF-EGFR induced activation of ERK and PI3 K-AKT pathways. J. Mol. Neurosci. 55, 519-524. (doi:10. 1007/s12031-014-0375-7)
52. Lv B et al. 2015 CXCR4 signaling induced epithelial-mesenchymal transition by PI3 K/AKT and ERK pathways in glioblastoma. Mol. Neurobiol. 52, 1263-1268. (doi:10.1007/ s12035-014-8935-y)
53. Liao A et al. 2016 SDF-1/CXCR4 axis regulates cell cycle progression and epithelial–mesenchymal transition via up-regulation of survivin in glioblastoma. Mol. Neurobiol.53, 210-215.(doi:10.1007/s12035-014-9006-0)
54. Iser IC, Pereira MB, Lenz G, Wink MR. 2016 The epithelial-to-mesenchymal transition-like process in glioblastoma: an updated systematic review and in silico investigation. Med. Res. Rev. 37, 271-313. (doi:10.1002/med.21408)
55. Redzic JS, Gomez JD, Hellwinkel JE, Anchordoquy TJ, Graner MW. 2016 Proteomic analyses of brain tumor cell lines amidst the unfolded protein response. Oncotarget 7, 47831-47847. (doi:10.18632/ oncotarget.10032)
56. Chetram MA, Hinton CV. 2012 PTEN regulation of ERK1/2 signaling in cancer. J. Recept. Signal Transduct. Res. 32, 190-195. (doi:10.3109/10799893.2012.695798)
57. Steelman LS et al. 2008 Contributions of the Raf/MEK/ERK, PI3 K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 22, 686-707. (doi:10.1038/leu.2008.26)
58. Dreesen O, Brivanlou AH. 2007 Signaling pathways in cancer and embryonic stem cells. Stem Cell Rev. 3, 7-17. (doi:10.1007/s12015-007-0004-8)
59. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. 2004 JAK/STAT, Raf/MEK/ ERK, PI3 K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18, 189-218. (doi:10.1038/sj.leu.2403241)
60. Meek DW. 2015 Regulation of the p53 response and its relationship to cancer. Biochem. J. 469, 325-346. (doi:10.1042/BJ20150517)
61. Sofroniew MV, Vinters HV. 2010 Astrocytes: biology and pathology. Acta Neuropathol. 119, 7-35. (doi:10.1007/s00401-009-0619-8)
62. Lo Cicero A, Schiera G, Proia P, Saladino P, Savettieri G, Di Liegro CM, Di Liegro I. 2011 Oligodendroglioma cells shed microvesicles which contain TRAIL as well as molecular chaperones and induce cell death in astrocytes. Int. J. Oncol. 39, 1353-1357. (doi:10.3892/ijo.2011.1160)
63. Sundarraj N, Schachner M, Pfeiffer SE. 1975 Biochemically differentiated mouse glial lines carrying a nervous system specific cell surface antigen (NS-1). Proc. Natl Acad. Sci. USA 72, 1927-1931. (doi:10.1073/pnas.72.5.1927)
64. Vella LJ. 2014 The emerging role of exosomes in epithelial-mesenchymal-transition in cancer. Front. Oncol. 4, 361. (doi:10.3389/fonc.2014. 00361)
65. Atay S, Banskota S, Crow J, Sethi G, Rink L, Godwin AK. 2014 Oncogenic KIT-containing exosomes increase gastrointestinal stromal tumor cell invasion. Proc. Natl Acad. Sci. USA 111, 711-716. (doi:10.1073/pnas.1310501111)
66. Mu W, Rana S, Zoller M. 2013 Host matrix modulation by tumor exosomes promotes motility and invasiveness. Neoplasia 15, 875-887. (doi:10.1593/neo.13786)
67. Silva TA et al. 2016 AHNAK enables mammary carcinoma cells to produce extracellular vesicles that increase neighboring fibroblast cell motility. Oncotarget 7, 49998-50016. (doi:10.18632/oncotarget.10307)
68. Baroni S et al. 2016 Exosome-mediated delivery of miR-9 induces cancer-associated fibroblast-like properties in human breast fibroblasts. Cell Death Dis. 7, e2312. (doi:10.1038/cddis.2016.224)
69. Franco OE, Shaw AK, Strand DW, Hayward SW. 2010 Cancer associated fibroblasts in cancer pathogenesis. Semin. Cell Dev. Biol. 21, 33-39. (doi:10.1016/j. semcdb.2009.10.010)
70. Chen W et al. 2015 Glioma cells escaped from cytotoxicity of temozolomide and vincristine by communicating with human astrocytes. Med. Oncol. 32, 43. (doi:10.1007/s12032-015-0487-0)
71. Frisa PS, Walter EI, Ling L, Kung HJ, Jacobberger JW. 1996 Stepwise transformation of astrocytes by simian virus 40 large T antigen and epidermal growth factor receptor overexpression. Cell Growth Differ. 7, 223-233.
72. Rich JN, Guo C, McLendon RE, Bigner DD, Wang XF, Counter CM. 2001 A genetically tractable model of human glioma formation. Cancer Res. 61, 3556-3560.
73. Medvedev R, Hildt E, Ploen D. 2016 Look who’s talking-the crosstalk between oxidative stress and autophagy supports exosomal-dependent release of HCV particles. Cell Biol. Toxicol. 33, 211-231. (doi:10.1007/s10565-016-9376-3)
74. van Dongen HM, Masoumi N, Witwer KW, Pegtel DM. 2016 Extracellular vesicles exploit viral entry routes for cargo delivery. Microbiol. Mol. Biol. Rev. 80, 369-386. (doi:10.1128/MMBR.00063-15)
75. Anderson MR, Kashanchi F, Jacobson S. 2016 Exosomes in viral disease. Neurotherapeutics 13, 535-546. (doi:10.1007/s13311-016-0450-6)
76. Meckes Jr DG. 2015 Exosomal communication goes viral. J. Virol. 89, 5200-5203. (doi:10.1128/JVI. 02470-14)
77. Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A, Rak J. 2008 Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat. Cell Biol. 10, 619-624. (doi:10.1038/ncb1725)
78. Neviani P, Fabbri M. 2015 Exosomic microRNAs in the tumor microenvironment. Front. Med. 2, 47. (doi:10.3389/fmed.2015.00047)
79. Stupp R et al. 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl. J. Med. 352, 987-996. (doi:10.1056/NEJMoa043330)
80. Domingo-Musibay E, Galanis E. 2015 What next for newly diagnosed glioblastoma? Future Oncol. 11, 3273-3283. (doi:10.2217/fon.15.258)
81. Tosoni A, Franceschi E, Poggi R, Brandes AA. 2016 Relapsed glioblastoma: treatment strategies for initial and subsequent recurrences. Curr. Treat. Options Oncol. 17, 49. (doi:10.1007/s11864-016-0422-4)
82. Braunstein S, Nakamura JL. 2013 Radiotherapy-induced malignancies: review of clinical features, pathobiology, and evolving approaches for mitigating risk. Front Oncol. 3, 73. (doi:10.3389/ fonc.2013.00073)
83. Yip S, Miao J, Cahill DP, Iafrate AJ, Aldape K, Nutt CL, Louis DN. 2009 MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin. Cancer Res. 15, 4622-4629. (doi:10.1158/1078-0432.CCR-08-3012)
84. Sato Y, Kurose A, Ogawa A, Ogasawara K, Traganos F, Darzynkiewicz Z, Sawai T. 2009 Diversity of DNA damage response of astrocytes and glioblastoma cell lines with various p53 status to treatment with etoposide and temozolomide. Cancer Biol. Ther. 8, 452-457. (doi:10.4161/cbt.8.5.7740)
85. Prasad G, Haas-Kogan DA. 2009 Radiation-induced gliomas. Expert Rev. Neurother 9, 1511-1517. (doi:10.1002/pmic.200800802)
86. Liu J, Zhang C, Feng Z. 2014 Tumor suppressor p53 and its gain-of-function mutants in cancer. Acta Biochim. Biophys. Sin 46, 170-179. (doi:10.1093/ abbs/gmt144)
87. 2/2 astrocytes and render these cells gliomagenic in the brain of immunocompetent mice. PLoS ONE 8, e56691. (doi:10.1371/journal.pone.0056691)